Overactive Bladder (OAB) Therapeutics Market Report
Overactive Bladder (OAB) Therapeutics Market, By Therapy (Anticholinergics, Mirabegron, Neurostimulation, Intravesical Instillation, Others), By Disease Type (Idiopathic Overactive Bladder, Neurogenic Overactive Bladder), and Region - COVID-19 Impact Analysis and Forecast to 2026.
This market research report provides in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global Overactive Bladder (OAB) Therapeutics market. The historic years considered for the study are 2016-2019, the base year is 2020, the estimated year is 2021, and the forecast period is 2022-2026.
Overactive Bladder (OAB) Therapeutics Market, By Therapy (Anticholinergics, Mirabegron, Neurostimulation, Intravesical Instillation, Others), By Disease Type (Idiopathic Overactive Bladder, Neurogenic Overactive Bladder), and Region - COVID-19 Im...
Impact of COVID-19 on Overactive Bladder (OAB) Therapeutics Market
Covid-19 has impacted the market dynamics, competition, and global supply chain. The revenues have gone down in 2020 and may resume an uptrend gradually from 2021. Companies optimizing their operation and strategy will sustain and beat the competition.
Note: The summary below might not have included insights on covid impact since we have large number of reports.
The Overactive Bladder (OAB) Therapeutics Market is estimated to grow from USD 3.6 billion in 2020 to USD 4.3 billion by 2026 at a healthy CAGR of 3.0% during the forecast period.
Overactive bladder (OAB) may be a medical syndrome, defined by urinary incontinence usually characterized by high urine frequency. The common symptoms of OAB include high urinary frequency, urgency, and urinary incontinence. These drugs act by antagonizing cholinergic receptors that provide relief from frequent urination.
Key players operating in the Overactive Bladder (OAB) Therapeutics market are-
Growing incidence of diseases, such as Parkinson’s disease, which leads to overactive bladder disorder, and rising geriatric population, are key factors propelling the market growth. Urinary incontinence generally rises with aging. OAB has a major negative impact on the quality of life and health of the aged population. With the rising burden of OAB, coupled with other urinary diseases, the growth of the overactive bladder treatment market is expected to be high. Other factors, such as the development of innovative intravesical therapies and aggressive marketing by pharmaceutical companies, are anticipated to offer lucrative growth opportunities.
Based on therapy, the overactive bladder (OAB) Therapeutics market is classified into anticholinergics, mirabegron, neurostimulation, intravesical installation, and others. The anticholinergics segment held a significant market share in 2020 and is estimated to register a healthy CAGR during the forecast timeline. This is mainly attributed to the high prevalence of overactive bladder. Due to bladder muscle weakness post-pregnancy and menopause, women are more vulnerable to the condition. The growing competition among the market players may lead to a decrease in the overall cost of treatment, during the forecast period, which bolsters the segment growth.
By region, the North American market accounted for a significant share in 2020 and is expected to grow at a substantial CAGR in the following years. This is mainly ascribed to its well-established healthcare industry. With reimbursement of overactive bladder treatment, the rising prevalence of the disease with rising age, and the large presence of major players, the market is likely to boost the market growth. Due to the growing prevalence of bladder over-activity, healthcare expenditure, geriatric population, and awareness about overactive bladder treatments, thereby proliferates the regional market growth.
The COVID-19 outbreak has moderately affected the Overactive Bladder (OAB) Therapeutics industry. The virus outbreak has turned the lives of people worldwide, with the number of cases increasing rapidly. The COVID-19 crisis has reduced the number of visits to hospitals and postponement of urology to curb the spread of the virus, thus affecting the market growth amid the pandemic.
Here is the list of the group of customers that the overactive bladder therapeutics market hopes to have the greatest opportunity to convert-
Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at email@example.com.
The overactive bladders therapeutics market is expected to witness an impressive growth of 3.0% CAGR in the coming years.
Allergan PLC (US), Astellas Pharma Inc. (Japan), Cogentix Medical Inc. (US), Endo International PLC (Ireland), Hisamitsu Pharmaceutical Co. Inc. (Japan), Johnson & Johnson (US), Medtronic PLC (Ireland), Pfizer Inc. (US), Sanofi (France), and Teva Pharmaceutical Industries Limited (Israel) are among the key players in the overactive bladders therapeutics market.
The overactive bladder therapeutics market size is expected to reach USD 4.3 billion in the foreseeable future.
The anticholinergics segment is expected to register healthy CAGR in the overactive bladders therapeutics market in the coming years.
North America is expected to grow at a substantial CAGR in the overactive bladders therapeutics market in the next five years.
Overactive Bladder (OAB) therapeutics vendors, Overactive Bladder (OAB) therapeutics retailers, Urology clinics, Hospitals are the target audience in the overactive bladders therapeutics market.